Mode
Text Size
Log in / Sign up

High-grade glioma

Part of Cancer

4 published articles · Updated continuously

Clinical Trial Landscape

Clinical Trials for High-grade glioma

7 trials tracked for High-grade glioma.

7Trials tracked
0Phase 3 & 4
0Recruiting
0With published results
Phase distribution
Phase 2 6 Phase 1 1
  1. Phase 2 A Study of Bevacizumab (Avastin) in Combination With Temozolomide (TMZ) and Radiotherapy in Paediatric and Adolescent Participants With High-Grade Glioma Completed
  2. Phase 2 Safety and Efficacy Study of TH-302 CNS Penetration in Recurrent High Grade Astrocytoma Following Bevacizumab Completed
  3. Phase 2 A Proof-of-concept Study to Assess the Ability of [18F]AH-111585 PET Imaging to Detect Tumours and Angiogenesis Completed
  4. Phase 2 Trial of Newly Diagnosed High Grade Glioma Treated With Concurrent Radiation Therapy, Temozolomide and BMX-001 Completed
  5. Phase 2 Low Dose Radiation Therapy for Glioblastoma Multiforme Completed
  6. Phase 2 Phase 2a Study of CAN-2409 With Standard Radiation Therapy for Malignant Glioma Completed
Show 1 more trials
  1. Phase 1 HUMC 1612: Optune NovoTTF-200A System Completed

Showing the 7 most-cited and recently-updated of 7 trials. Browse the full registry →

Trial data sourced from ClinicalTrials.gov. Counts describe the research landscape and are not a treatment recommendation. Informational only — not medical advice.

HCP Mode — summaries include clinical detail, trial data, and statistical outcomes.
Patient Mode — summaries use plain language, avoiding clinical jargon.

Research across Cancer

Related studies from across the Cancer family.

MRI Radiomics Predicts TERTp Mutation in Glioma with Moderate Accuracy
Oncology Meta-analysis
MRI Radiomics Predicts TERTp Mutation in Glioma with Moderate Accuracy MRI Radiomics Help Predict TERTp Mutation in Glioma Patients
Meta-analysis of 14 studies shows MRI radiomics predicts TERTp mutation in glioma with AUC 0.79; combined models improve accuracy to 0.82.
New analysis shows MRI-based radiomics can help predict specific genetic mutations in glioma, potentially aiding early diagnosis and treatme…
NODI parameters ODI and V-ISO differentiate gliomas from brain metastases in contrast-enhancing regions
Radiology & Imaging Meta-analysis
NODI parameters ODI and V-ISO differentiate gliomas from brain metastases in contrast-enhancing regions Brain scan technique helps tell gliomas from metastases
This meta-analysis evaluates the use of Neurite orientation dispersion and density imaging (NODDI) to distinguish gliomas from brain metasta…
A new imaging method may help doctors distinguish between gliomas and brain metastases without invasive biopsy.
Follicular T cell subsets and tertiary lymphoid structures may guide immunotherapy in ovarian cancer
Allergy & Immunology Sys. Review
Follicular T cell subsets and tertiary lymphoid structures may guide immunotherapy in ovarian cancer New immune targets offer hope for ovarian cancer patients
This narrative review synthesizes evidence on follicular T cell subsets, tertiary lymphoid structures, and other immune features in ovarian …
A review highlights new immune system features that could help doctors predict treatment success and find better ways to fight ovarian cance…
Intensity-modulated radiotherapy reduces acute and delayed G2+GI toxicities versus 3D-CRT in high-risk prostate cancer
Urology RCT
Intensity-modulated radiotherapy reduces acute and delayed G2+GI toxicities versus 3D-CRT in high-risk prostate cancer Post hoc analysis shows IMRT reduces radiation side effects for high-risk prostate cancer
This post hoc analysis of a Phase III randomized controlled trial evaluated intensity-modulated radiotherapy (IMRT) versus three-dimensional…
A post hoc analysis of a Phase III trial found that intensity-modulated radiotherapy reduced radiation side effects compared to older techni…
Deep learning models for glioma segmentation achieve high whole tumor accuracy with DSC 0.860
Oncology Meta-analysis
Deep learning models for glioma segmentation achieve high whole tumor accuracy with DSC 0.860 New AI tools show high accuracy for mapping brain tumors before surgery
This systematic review and meta-analysis of 36 deep learning models for preoperative glioma segmentation found high whole tumor segmentation…
AI models mapped brain tumors with high accuracy, but performance varied. Training on specific datasets helped, yet no single factor fully e…
Case report details multimodal treatment for aggressive thyroid carcinoma
Oncology Sys. Review
Case report details multimodal treatment for aggressive thyroid carcinoma First new treatment combination in six months stabilizes advanced thyroid cancer
A 61-year-old man with papillary thyroid carcinoma achieved disease stabilization after thyroidectomy, radiotherapy, and targeted therapy. T…
A 61-year-old man with advanced thyroid cancer saw his disease stop growing after a specific mix of treatments within six months of his diag…
Systematic review of preclinical CBD effects in canine cancers
Cardiology Meta-analysis
Systematic review of preclinical CBD effects in canine cancers Lab tests suggest CBD may help treat cancer in dogs
This is a systematic review of preclinical studies on cannabidiol for canine cancers. It synthesizes evidence of antiproliferative and proap…
Lab tests suggest CBD may help treat cancer in dogs by slowing growth and triggering cell death, though human use remains unproven.
Case report of YL205 antibody-drug conjugate in platinum-resistant ovarian carcinoma
Infectious Disease Sys. Review
Case report of YL205 antibody-drug conjugate in platinum-resistant ovarian carcinoma First patient achieves complete response with new ovarian cancer drug YL205
This is a single-patient case report of a 40-year-old woman with platinum-resistant, BRCA-wildtype high-grade serous ovarian carcinoma treat…
A single patient with advanced ovarian cancer achieved a complete response after 24 weeks of treatment with YL205, a new antibody-drug conju…
Systematic review explores metabolic-immune axis in glioma progression and resistance
Diabetes & Endocrinology Sys. Review
Systematic review explores metabolic-immune axis in glioma progression and resistance Metabolic-immune link in glioma opens new treatment avenues
This systematic review synthesizes evidence on the metabolic-immune interplay in glioma. It finds that metabolic reprogramming and immune mi…
A systematic review reveals how metabolic reprogramming and immune evasion work together in glioma, pointing to new targets for therapy.
Systematic Review Links Neural Circuit Disturbances to Glioma Symptoms and Survival
Oncology Sys. Review
Systematic Review Links Neural Circuit Disturbances to Glioma Symptoms and Survival Brain tumor growth linked to disrupted neural circuits
This systematic review synthesizes evidence that circuit-level disturbances in the neural microenvironment correspond with glioma-related ep…
A new review shows that glioma disrupts brain circuits, linking seizures, mood changes, and survival. Could rewiring the brain help treat tu…
Review of glioma organoid models for mechanistic discovery and therapy development
Oncology Sys. Review
Review of glioma organoid models for mechanistic discovery and therapy development Finally Lab-Grown Brain Models Could Speed Up Glioma Treatments
This narrative review summarizes glioma organoid model systems for studying tumor-neural interactions. It concludes these models provide a f…
• Tiny lab-grown brains mimic real tumor behavior better than old methods • Kids and adults fighting deadly brain cancers like glioblastoma …
Time to biochemical progression predicts second events in high-risk prostate cancer
Drug Pipeline RCT
Time to biochemical progression predicts second events in high-risk prostate cancer Longer time to progression predicts better outcomes in prostate cancer
This phase 3 RCT of 413 men with high-risk localized prostate cancer found that a longer time from randomization to biochemical progression …
Men with high-risk prostate cancer who had a longer time before their cancer worsened were less likely to have further progression or spread…

Questions about High-grade glioma

Does delivering CAR T-cells locally reduce severe side effects in high-grade glioma?

Delivering CAR T-cells directly into the tumor or brain ventricles significantly lowers severe side effects compared to giving them through the bloodstream for high-grade glioma patients.

Full answer →
Can a specific gene signature predict survival for high-grade glioma patients?

Yes, specific gene signatures can predict survival for high-grade glioma patients by analyzing tumor biology, immune interactions, and cellular processes like autophagy.

Full answer →
What is the most common way high-grade glioma comes back after standard treatment?

After standard surgery and radiation, high-grade glioma most often returns in the center of the original tumor area or just at the edge of the radiation field.

Full answer →